Resultados de procura - C. Lance Cowey

  • Mostrando 1 - 16 Resultados de 16
Limitar resultados
  1. 1
    VHL gene mutations in renal cell carcinoma: Role as a biomarker of disease outcome and drug efficacy

    VHL gene mutations in renal cell carcinoma: Role as a biomarker of disease outcome and drug efficacy por C. Lance Cowey, W. Kimryn Rathmell

    Publicado 2009
    Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  2. 2
    Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma

    Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma por Omid Hamid, C. Lance Cowey, M Offner, Mark B. Faries, Richard D. Carvajal

    Publicado 2019
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  3. 3
    Real-world treatment outcomes in patients with metastatic Merkel cell carcinoma treated with chemotherapy in the USA

    Real-world treatment outcomes in patients with metastatic Merkel cell carcinoma treated with chemotherapy in the USA por C. Lance Cowey, Lisa Mahnke, Janet L. Espirito, Christoph Helwig, Dina Oksen, Murtuza Bharmal

    Publicado 2017
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  4. 4
    Clinical outcomes among unresectable, locally advanced, and metastatic cutaneous squamous cell carcinoma patients treated with systemic therapy

    Clinical outcomes among unresectable, locally advanced, and metastatic cutaneous squamous cell carcinoma patients treated with systemic therapy por C. Lance Cowey, Nicholas J. Robert, Janet L. Espirito, Kalatu Davies, Jennifer R. Frytak, Israel Lowy, Matthew G. Fury

    Publicado 2020
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  5. 5
    <scp>FDG</scp>‐<scp>PET</scp> as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer

    <scp>FDG</scp>‐<scp>PET</scp> as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer por James L. Chen, Daniel Appelbaum, Masha Kocherginsky, C. Lance Cowey, W. Kimryn Rathmell, David F. McDermott, Walter M. Stadler

    Publicado 2013
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  6. 6
    Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab

    Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab por Jorge A. García, Thomas E. Hutson, Paul Elson, C. Lance Cowey, Timothy D. Gilligan, Cheryl Nemec, Robert Dreicer, Ronald M. Bukowski, Brian I. Rini

    Publicado 2010
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  7. 7
    Neoadjuvant Clinical Trial With Sorafenib for Patients With Stage II or Higher Renal Cell Carcinoma

    Neoadjuvant Clinical Trial With Sorafenib for Patients With Stage II or Higher Renal Cell Carcinoma por C. Lance Cowey, Chirag Amin, Raj S. Pruthi, Eric Wallen, Matthew E. Nielsen, Gayle Grigson, Cathy Watkins, Keith V. Nance, Jeffrey M. Crane, Mark Jalkut, Dominic T. Moore, William Y. Kim, Paul A. Godley, Young E. Whang, Julia R. Fielding, W. Kimryn Rathmell

    Publicado 2010
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  8. 8
    Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials

    Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized... por Dirk Schadendorf, Jedd D. Wolchok, F. Stephen Hodi, Vanna Chiarion‐Sileni, René González, Piotr Rutkowski, Jean-Jacques Grob, C. Lance Cowey, Christopher D. Lao, Jason Chesney, Caroline Robert, Kenneth F. Grossmann, David F. McDermott, Damian Walker, Rafia Bhore, James Larkin, Michael A. Postow

    Publicado 2017
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  9. 9
    A phase 2 study of glembatumumab vedotin, an antibody‐drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma

    A phase 2 study of glembatumumab vedotin, an antibody‐drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma por Patrick A. Ott, Anna C. Pavlick, Douglas B. Johnson, Lowell L. Hart, Jeffrey R. Infante, Jason J. Luke, Jose Lutzky, Neal E. Rothschild, Lynn E. S̄pitler, C. Lance Cowey, Aaron Alizadeh, April K.S. Salama, Yi He, Thomas Hawthorne, Rebecca G. Bagley, Joshua Zhang, Christopher Turner, Omid Hamid

    Publicado 2019
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  10. 10
    Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial

    Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial por Jeffrey S. Weber, Michele Del Vecchio, Mario Mandalà, Helen Gogas, Ana Arance, Stéphane Dalle, C. Lance Cowey, Michael Schenker, Jean‐Jacques Grob, Vanna Chiarion‐Sileni, Iván Márquez‐Rodas, Marcus O. Butler, Michele Maio, Mark R. Middleton, Tania Tang, Abdel Saci, Veerle de Pril, Maurice Lobo, James Larkin, Paolo A. Ascierto

    Publicado 2019
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  11. 11
    A Single-Arm, Open-Label, Expanded Access Study of Vemurafenib in Patients With Metastatic Melanoma in the United States

    A Single-Arm, Open-Label, Expanded Access Study of Vemurafenib in Patients With Metastatic Melanoma in the United States por Lawrence E. Flaherty, Omid Hamid, Gerald P. Linette, Lynn M. Schuchter, Sigrun Hallmeyer, René González, C. Lance Cowey, Anna C. Pavlick, Fred J. Kudrik, Brendan D. Curti, David H. Lawson, Paul B. Chapman, Kim Margolin, Antoni Ribas, David F. McDermott, Keith T. Flaherty, Lee D. Cranmer, F. Stephen Hodi, Bann‐Mo Day, R. Linke, John D. Hainsworth

    Publicado 2014
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  12. 12
    Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma

    Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma por Jedd D. Wolchok, Vanna Chiarion‐Sileni, René González, Jean‐Jacques Grob, Piotr Rutkowski, Christopher D. Lao, C. Lance Cowey, Dirk Schadendorf, John Wagstaff, Reinhard Dummer, Pier Francesco Ferrucci, Michael Smylie, Marcus O. Butler, Andrew G. Hill, Iván Márquez‐Rodas, John B.A.G. Haanen, Massimo Guidoboni, Michele Maio, Patrick Schöffski, Matteo S. Carlino, Célèste Lebbé, Grant A. McArthur, Paolo A. Ascierto, Gregory A. Daniels, Georgina V. Long, Tuba Öcek Baş, Corey Ritchings, James Larkin, F. Stephen Hodi

    Publicado 2021
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  13. 13
    Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

    Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma por James Larkin, Vanna Chiarion‐Sileni, René González, Jean‐Jacques Grob, C. Lance Cowey, Christopher D. Lao, Dirk Schadendorf, Reinhard Dummer, Michael Smylie, Piotr Rutkowski, Pier Francesco Ferrucci, Andrew G. Hill, John Wagstaff, Matteo S. Carlino, John B.A.G. Haanen, Michele Maio, Iván Márquez‐Rodas, Grant A. McArthur, Paolo A. Ascierto, Georgina V. Long, Margaret K. Callahan, Michael A. Postow, Kenneth F. Grossmann, Mario Sznol, Brigitte Dréno, Lars Bastholt, Arvin Yang, Linda M. Rollin, Christine E. Horak, F. Stephen Hodi, Jedd D. Wolchok

    Publicado 2015
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  14. 14
    Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

    Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma por Jeffrey S. Weber, Mario Mandalà, Michele Del Vecchio, Helen Gogas, Ana Arance, C. Lance Cowey, Stéphane Dalle, Michael Schenker, Vanna Chiarion‐Sileni, Iván Márquez‐Rodas, Jean-Jacques Grob, Marcus O. Butler, Mark R. Middleton, Michele Maio, Victoria Atkinson, Paola Queirolo, René González, Ragini R. Kudchadkar, Michael Smylie, Nicolás Meyer, Laurent Mortier, Michael B. Atkins, Georgina V. Long, Shailender Bhatia, Célèste Lebbé, Piotr Rutkowski, Kenji Yokota, Naoya Yamazaki, Tae M. Kim, Veerle de Pril, Javier Sabater, Anila Qureshi, James Larkin, Paolo A. Ascierto

    Publicado 2017
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  15. 15
    Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

    Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma por James Larkin, Vanna Chiarion‐Sileni, René González, Jean‐Jacques Grob, Piotr Rutkowski, Christopher D. Lao, C. Lance Cowey, Dirk Schadendorf, John Wagstaff, Reinhard Dummer, Pier Francesco Ferrucci, Michael Smylie, David Hogg, Andrew F. Hill, Iván Márquez‐Rodas, John B.A.G. Haanen, Massimo Guidoboni, Michele Maio, Patrick Schöffski, Matteo S. Carlino, Célèste Lebbé, Grant A. McArthur, Paolo A. Ascierto, Gregory A. Daniels, Georgina V. Long, Lars Bastholt, Jasmine I. Rizzo, Ágnes Balogh, Andriy Moshyk, F. Stephen Hodi, Jedd D. Wolchok

    Publicado 2019
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  16. 16
    Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

    Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma por Jedd D. Wolchok, Vanna Chiarion‐Sileni, René González, Piotr Rutkowski, Jean‐Jacques Grob, C. Lance Cowey, Christopher D. Lao, John Wagstaff, Dirk Schadendorf, Pier Francesco Ferrucci, Michael Smylie, Reinhard Dummer, Andrew G. Hill, David Hogg, John B.A.G. Haanen, Matteo S. Carlino, Oliver Bechter, Michele Maio, Iván Márquez‐Rodas, Massimo Guidoboni, Grant A. McArthur, Célèste Lebbé, Paolo A. Ascierto, Georgina V. Long, Jonathan Cebon, Jeffrey A. Sosman, Michael A. Postow, Margaret K. Callahan, Damian Walker, Linda Rollin, Rafia Bhore, F. Stephen Hodi, James Larkin

    Publicado 2017
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:

Ferramentas de procura: